GlaxoSmithKline Lobbies for Increased Regulation of E-Cigarettes
GlaxoSmithKline Plc (NYSE:GSK), maker of the smoking cessation gum Nicorette, is calling for stricter regulation of e-cigarettes. Glaxo’s vice president of its consumer health business, Sophie Crousse, pressed the European Commission to follow the UK’s lead and require e-cigarettes to be labeled as medicines, similar to other nicotine-replacement therapies that are used to promote smoking cessation, Bloomberg reports.
The European Commission is currently in the midst of revising the Tobacco Products Directive in order to help regulate products that don’t necessarily contain tobacco, but may contain nicotine and are associated with tobacco use, such as e-cigarettes.
In December, the European Parliament as well as representatives of various European governments reached a consensus that the strongest types of e-cigarettes — those containing more than 20 milligrams per milliliter of nicotine — would need to be properly authorized as medicine; a compromise accord is scheduled to be voted on next week, Bloomberg reports.